TriLink BioTechnologies, a subsidiary of Maravai LifeSciences Holdings Inc., has introduced its first mRNA synthesis kit featuring the innovative CleanCap® capping technology. This new all-in-one IVT kit is designed to deliver up to twice as much mRNA and reduce double-stranded RNA by up to 85% compared to existing kits on the market. The streamlined synthesis process enhances yield and performance. To celebrate the launch, TriLink is donating the initial kits to leading academic institutions in the U.S. and Europe. With over 25 years of experience, TriLink is a leader in nucleic acid product development, playing a vital role in advancing mRNA and oligonucleotide-based therapeutic innovations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.